Novartis AG (NYSE:NVS) has been assigned a consensus rating of “Hold” from the seventeen brokerages that are covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $83.19.
A number of research analysts recently issued reports on NVS shares. Zacks Investment Research downgraded Novartis from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Bank of America cut Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Nord/LB reissued a “neutral” rating on shares of Novartis in a report on Wednesday, December 27th. UBS Group reissued a “neutral” rating on shares of Novartis in a report on Monday, January 15th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a report on Thursday, January 18th.
Shares of Novartis (NVS) traded up $0.23 during trading hours on Wednesday, hitting $86.91. The company had a trading volume of 983,100 shares, compared to its average volume of 1,715,442. The company has a market cap of $201,410.11, a P/E ratio of 26.74, a PEG ratio of 2.02 and a beta of 0.73. The company has a current ratio of 1.21, a quick ratio of 0.91 and a debt-to-equity ratio of 0.31. Novartis has a 52 week low of $72.67 and a 52 week high of $94.19.
Novartis (NYSE:NVS) last announced its quarterly earnings data on Wednesday, January 24th. The company reported $1.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.04. The company had revenue of $12.92 billion during the quarter, compared to the consensus estimate of $12.65 billion. Novartis had a return on equity of 16.03% and a net margin of 15.69%. The firm’s revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.14 EPS. research analysts predict that Novartis will post 5.36 EPS for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. WFG Advisors LP raised its holdings in shares of Novartis by 38.1% during the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock worth $102,000 after acquiring an additional 337 shares in the last quarter. Wealthcare Advisory Partners LLC purchased a new stake in shares of Novartis during the 3rd quarter worth approximately $106,000. Cable Hill Partners LLC raised its holdings in shares of Novartis by 588.8% during the 3rd quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock worth $112,000 after acquiring an additional 1,107 shares in the last quarter. Pinnacle Wealth Planning Services Inc. purchased a new stake in shares of Novartis during the 4th quarter worth approximately $113,000. Finally, Calton & Associates Inc. purchased a new stake in shares of Novartis during the 4th quarter worth approximately $118,000. 10.96% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/19/novartis-ag-nvs-given-average-rating-of-hold-by-brokerages-2.html.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.